Printer Friendly

Neoprobe Interviewed by; CFO Provides Business Update.

DUBLIN, Ohio -- Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that the Company is presently featured in an online interview at CFO Brent Larson discusses the Company's biomedical product offerings and development activities as well as other matters impacting the future performance of the company.

The Neoprobe Corporation interview is available at If you are not already a subscriber, you may sign up for free by clicking on the "Sign me up - FREE!" button at the top of the page. After establishing your user ID and password, click on the "Submit" button at the top of the page. This will register you and send you back to the home page. You may access the interview by clicking on the "Interview" button on the toolbar near the top of the page and entering the trading symbol "NEOP" in the Search Archive dialog box mid-way down the page.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix(R) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek(TM) and RIGScan(R) CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 31, 2006
Previous Article:Fitch Ratings Affirms CMBS/Realty One Securitization Trust 2002-1.
Next Article:Fitch Affirms Banco Santander Serfin's Ratings.

Related Articles
Neoprobe Announces First Quarter Results; First Quarter Device Sales Increase 20% Over Prior Year; Business Update Provided and Conference Call...
CEO Discusses Product Offerings and Corporate Strategy with in Online Interview.
Neoprobe Announces Second Quarter Results; Second Quarter Device Sales Increase 26% - Business Update Provided and Conference Call Scheduled.
Neoprobe 3rd Quarter 2005 Earnings Conference Call Invitation; Conference Call Scheduled for 11:00 a.m., Thursday, November 3, 2005.
Neoprobe Provides Third Quarter Results & Development Update; Conference Call Scheduled.
Neoprobe Announces Second Quarter Results; Business Update Provided and Conference Call Scheduled.
Neoprobe to Present at Wall Street Analyst Forum; CFO To Provide Business Update.
Neoprobe Announces Third Quarter Results.
Neoprobe 3rd Quarter 2006 Earnings Conference Call Invitation.
Neoprobe Announces First Quarter Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters